tuberculosis, drug resistance, randomised clinical trial, pragmatic trial, whole genome sequencing, precision medicine
tuberculosis, antimicrobial resistance, genomics, next generation sequencing, whole genome sequencing, variant interpretation
tuberculosis, drug-resistance, whole genome sequencing, health economics, cost-effectiveness, within-trial analysis, DALY, ICER, INMB, ROI